PPIDT00005

Drug Information
NameEtanercept
SequenceLPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00005
Typebiotech
IndicationEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.[L48526]
Dosage Forms
Form Route Strength
Injection, solution Parenteral
25 MG
Injection, solution Parenteral
50 MG
Injection Subcutaneous
50 MG/ML
Injection, powder, for solution Subcutaneous
10 MG
Injection, powder, for solution Subcutaneous
25 MG/ML
Injection, powder, for solution Subcutaneous
50 MG
Injection, powder, lyophilized, for solution; kit Subcutaneous
25 mg/1mL
Injection, solution Subcutaneous
25 MG
Injection, solution Subcutaneous
50 MG
Kit Subcutaneous
Kit; liquid; powder, for solution Subcutaneous
Powder Subcutaneous
25 MG
Solution Parenteral; Subcutaneous
50 MG
Solution Subcutaneous
25 mg/0.5mL
Solution Subcutaneous
25.000 mg
Solution Subcutaneous
50 mg / mL
Solution Subcutaneous
50 mg/1mL
Solution —
25 mg/0.5ml
Injection, powder, lyophilized, for solution Subcutaneous
5000000 mg
Injection Subcutaneous
25 mg/0.5ml
Powder Parenteral
25 MG
Injection Subcutaneous
25 mg
Injection Subcutaneous
Injection Subcutaneous
50 mg
Injection, solution Subcutaneous
50 mg/mL
Solution Subcutaneous
2500000 mg
Solution Subcutaneous
5000000 mg
Injection, solution Parenteral; Subcutaneous
25 MG
Injection, solution Parenteral; Subcutaneous
50 MG
Solution Subcutaneous
25 mg / 0.5 mL
Solution Subcutaneous
25.00 mg
Solution Subcutaneous
50 mg
Injection, powder, lyophilized, for solution Subcutaneous
2500000 mg
Injection, powder, lyophilized, for solution Subcutaneous
25 mg
— Subcutaneous
25.0 mg
Injection, solution Subcutaneous
25 mg/0.5mL
Injection, solution Subcutaneous
50 mg/1mL
Injection, powder, for solution Subcutaneous
25 mg
Solution —
25 mg
Solution —
50 mg
Solution —
50 mg/ml
Solution Subcutaneous
50 mg / 1 mL
Injection, powder, for solution Intramuscular
25 mg/25mg
Injection, solution —
50 mg
Powder —
25 mg/1vial
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P01375 TNF Tumor necrosis factor Homo sapiens inhibitor|antibody Link
target P01374 LTA Lymphotoxin-alpha Homo sapiens antibody Link
target P12314 FCGR1A High affinity immunoglobulin gamma Fc receptor I Homo sapiens ligand Link
target P12318 FCGR2A Low affinity immunoglobulin gamma Fc region receptor II-a Homo sapiens ligand Link
target P31994 FCGR2B Low affinity immunoglobulin gamma Fc region receptor II-b Homo sapiens ligand Link
target P31995 FCGR2C Low affinity immunoglobulin gamma Fc region receptor II-c Homo sapiens ligand Link
target P08637 FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A Homo sapiens ligand Link
target O75015 FCGR3B Low affinity immunoglobulin gamma Fc region receptor III-B Homo sapiens ligand Link
target P02745 C1QA Complement C1q subcomponent subunit A Homo sapiens ligand Link